Abstract
Nasal natural killer/T-cell lymphoma (NNKTL) is associated with Epstein–Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination. Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematologic malignancies. The aim of the present study was to determine whether specific chemokines are produced by NNKTL. We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA. Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines. In addition, CCL17 and CCL22 were readily observed in the sera of NNKTL patients. The levels of these chemokines were significantly higher in patients than in healthy controls. Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients. Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines. Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.
Similar content being viewed by others
Abbreviations
- ADCC:
-
Antibody-dependent cellular cytotoxicity
- ATLL:
-
Adult T-cell leukemia/lymphoma
- CCL:
-
Chemokine (C-C motif) ligand
- CCR4:
-
C-C chemokine receptor 4
- EBV:
-
Epstein–Barr virus
- FBS:
-
Fetal bovine serum
- IL:
-
Interleukin
- IP-10:
-
Interferon-gamma-inducible protein-10
- LDH:
-
Lactate dehydrogenase
- LMP-1:
-
Latent membrane protein-1
- mAbs:
-
Monoclonal antibodies
- MDC:
-
Macrophage-derived chemokine
- miR:
-
Micro-RNA
- NK cell:
-
Natural killer cell
- NNKTL:
-
Nasal natural killer/T-cell lymphoma
- PBMCs:
-
Peripheral blood mononuclear cells
- PBS:
-
Phosphate-buffered saline
- TARC:
-
Thymus and activation-regulated chemokine
References
Harabuchi Y, Takahara M, Kishibe K, Moriai S, Nagato T, Ishii H (2009) Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. Int J Clin Oncol 14:181–190. doi:10.1007/s10147-009-0882-7
Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T (1990) Epstein–Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128–130
Emile JF, Boulland ML, Haioun C, Kanavaros P, Petrella T, Delfau-Larue MH, Bensussan A, Farcet JP, Gaulard P (1996) CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 87:1466–1473
Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, Demachi A, Sekine T, Yamamoto K, Shimizu N (2001) Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein–Barr virus. Blood 97:708–713
Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, Kon S (1996) Nasal T-cell lymphoma causally associated with Epstein–Barr virus: clinicopathologic, phenotypic, and genotypic studies. Cancer 77:2137–2149. doi:10.1002/(SICI)1097-0142(19960515)77:10<2137:AID-CNCR27>3.0.CO;2-V
Minarovits J, Hu LF, Imai S, Harabuchi Y, Kataura A, Minarovits-Kormuta S, Osato T, Klein G (1994) Clonality, expression and methylation patterns of the Epstein–Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. J Gen Virol 75(Pt 1):77–84
Nagato T, Kobayashi H, Kishibe K, Takahara M, Ogino T, Ishii H, Oikawa K, Aoki N, Sato K, Kimura S, Shimizu N, Tateno M, Harabuchi Y (2005) Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 11:8250–8257. doi:10.1158/1078-0432.CCR-05-1426
Takahara M, Kis LL, Nagy N, Liu A, Harabuchi Y, Klein G, Klein E (2006) Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer 119:2775–2783. doi:10.1002/ijc.22139
Moriai S, Takahara M, Ogino T, Nagato T, Kishibe K, Ishii H, Katayama A, Shimizu N, Harabuchi Y (2009) Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells. Clin Cancer Res 15:6771–6779. doi:10.1158/1078-0432.CCR-09-1052
Takahara M, Nagato T, Komabayashi Y, Yoshino K, Ueda S, Kishibe K, Harabuchi Y (2013) Soluble ICAM-1 secretion and its functional role as an autocrine growth factor in nasal NK/T cell lymphoma cells. Exp Hematol 41:711–718. doi:10.1016/j.exphem.2013.03.009
Yoshino K, Kishibe K, Nagato T, Ueda S, Komabayashi Y, Takahara M, Harabuchi Y (2013) Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27. Br J Haematol 160:331–342. doi:10.1111/bjh.12136
Komabayashi Y, Kishibe K, Nagato T, Ueda S, Takahara M, Harabuchi Y (2014) Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T-cell lymphoma. Am J Hematol 89:25–33. doi:10.1002/ajh.23570
Wang JM, Deng X, Gong W, Su S (1998) Chemokines and their role in tumor growth and metastasis. J Immunol Methods 220:1–17
Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS (2013) Chemokines in tumor progression and metastasis. Oncotarget 4:2171–2185
Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S (2002) Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol 13(Suppl 1):52–56
Laurence AD (2006) Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol 132:255–267. doi:10.1111/j.1365-2141.2005.05841.x
Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, Hieshima K, Tatsumi Y, Matsushima K, Hasegawa H, Kanamaru A, Kamihira S, Yamada Y (2002) Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99:1505–1511
Ishida T, Ishii T, Inagaki A, Yano H, Kusumoto S, Ri M, Komatsu H, Iida S, Inagaki H, Ueda R (2006) The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 20:2162–2168. doi:10.1038/sj.leu.2404415
Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, Shitara K, Ueda R (2010) Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 16:1520–1531. doi:10.1158/1078-0432.CCR-09-2697
Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591–1598. doi:10.1200/JCO.2009.25.3575
Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O (1997) The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 272:15036–15042
Nomiyama H, Imai T, Kusuda J, Miura R, Callen DF, Yoshie O (1998) Human chemokines fractalkine (SCYD1), MDC (SCYA22) and TARC (SCYA17) are clustered on chromosome 16q13. Cytogenet Cell Genet 81:10–11
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (2000) The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. Hematol J 1:53–66. doi:10.1038/sj/thj/6200013
Nagata H, Numata T, Konno A, Mikata I, Kurasawa K, Hara S, Nishimura M, Yamamoto K, Shimizu N (2001) Presence of natural killer-cell clones with variable proliferative capacity in chronic active Epstein–Barr virus infection. Pathol Int 51:778–785
Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M et al (1985) TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol 134:1623–1630
Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y, Takatsuki K (2000) A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14:922–930
Schneider U, Schwenk HU, Bornkamm G (1977) Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 19:621–626
Minowada J, Onuma T, Moore GE (1972) Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 49:891–895
Ravid Z, Goldblum N, Zaizov R, Schlesinger M, Kertes T, Minowada J, Verbi W, Greaves M (1980) Establishment and characterization of a new leukaemic T-cell line (Peer) with an unusual phenotype. Int J Cancer 25:705–710
Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J (1986) Hodgkin’s disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res 10:487–500
Nakayama T, Hieshima K, Nagakubo D, Sato E, Nakayama M, Kawa K, Yoshie O (2004) Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein–Barr virus. J Virol 78:1665–1674
Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113:6392–6402. doi:10.1182/blood-2009-03-209650
Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, Jarrett RF, Te Meerman GJ, Poppema S, van den Berg A (2008) Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 140:527–536. doi:10.1111/j.1365-2141.2007.06964.x
Takegawa S, Jin Z, Nakayama T, Oyama T, Hieshima K, Nagakubo D, Shirakawa AK, Tsuzuki T, Nakamura S, Yoshie O (2008) Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein–Barr virus-associated B-cell lymphoproliferative disorder. Cancer Sci 99:296–302. doi:10.1111/j.1349-7006.2007.00687.x
Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112:1424–1433. doi:10.1182/blood-2008-01-133769
Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C, Piris MA (2005) Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11:1467–1473. doi:10.1158/1078-0432.CCR-04-1869
Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R (2006) Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66:5716–5722. doi:10.1158/0008-5472.CAN-06-0261
Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103:1755–1762. doi:10.1182/blood-2003-07-2594
Ishii H, Takahara M, Nagato T, Kis LL, Nagy N, Kishibe K, Harabuchi Y, Klein E (2012) Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15. Int J Cancer 130:48–58. doi:10.1002/ijc.25969
Nieto JC, Canto E, Zamora C, Ortiz MA, Juarez C, Vidal S (2012) Selective loss of chemokine receptor expression on leukocytes after cell isolation. PLoS One 7:e31297. doi:10.1371/journal.pone.0031297
Hashimoto S, Nakamura K, Oyama N, Kaneko F, Tsunemi Y, Saeki H, Tamaki K (2006) Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. J Dermatol Sci 44:93–99. doi:10.1016/j.jdermsci.2006.08.004
Middeldorp JM, Pegtel DM (2008) Multiple roles of LMP1 in Epstein–Barr virus induced immune escape. Semin Cancer Biol 18:388–396. doi:10.1016/j.semcancer.2008.10.004
Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R (2009) Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol 183:4782–4791. doi:10.4049/jimmunol.0900699
Ishida T, Ueda R (2006) CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97:1139–1146. doi:10.1111/j.1349-7006.2006.00307.x
Kanazawa T, Hiramatsu Y, Iwata S, Siddiquey M, Sato Y, Suzuki M, Ito Y, Goshima F, Murata T, Kimura H (2014) Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res 20:5075–5084. doi:10.1158/1078-0432.CCR-14-0580
Acknowledgments
The authors thank Dr. Shimizu N (Tokyo Medical and Dental University) and Prof. Klein E (Karolinska Institute) for generously providing cell lines. This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI [Grant Numbers 24791735 (Kumai T), 23791869 (Nagato T), 25460430 (Kobayashi H), and 24390385 (Harabuchi Y)] and by National Institutes of Health (NIH) Grants [Grant Numbers R01CA136828 and R01CA157303 (Celis E)].
Conflict of interest
The authors have no financial conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Takumi Kumai and Toshihiro Nagato contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kumai, T., Nagato, T., Kobayashi, H. et al. CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. Cancer Immunol Immunother 64, 697–705 (2015). https://doi.org/10.1007/s00262-015-1675-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-015-1675-7